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Abstract
The global SARS-CoV-2 outbreak has been accompanied with severe socio-
economic and health burdens that will ripple through history. It is now known that
SARS-CoV-2 induces a cytokine storm that leads to acute respiratory distress syn-
drome and systemic organ damage. With no definitive nor safe therapy for COVID-
19 as well as the rise of viral variants the need for an urgent treatment modality is
paramount. Mesenchymal stem cells (MSCs) and their extracellular vesicles (EVs)
have long been praised for their anti-viral, anti-inflammatory and tissue regenera-
tive capabilities. MSCs and their EVs are now being studied for their possible use as
a treatment modality for COVID-19. In this review we explore their capabilities and
outline the evidence of their use in ALI, ARDS and COVID-19.
Keywords: COVID-19, Coronavirus, SARS-CoV-2, Mesenchymal stem cells,
Extracellular vesicles, Exosomes, Regenerative medicine
1. Introduction
Over the past several months, the world has had to endure another global
outbreak, the likes of which have not been seen since the Spanish flu pandemic of
1918 [1]. Coronavirus disease 2019 (COVID-19) caused from the virus now known
as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is understood to
undergo human-to-human transmission by respiratory droplets and known to cause
a broad range of symptoms contributing to its rapid spread [2]. As of February 14,
2021, there have been over 109 million reported cases and over 2.39 million deaths
worldwide, with the United States having over 27.6 million reported cases along
with over 484,000 deaths [3]. As cases continue to accumulate and cause significant
strain on medical resources and society, the need for an urgent, effective and safe
treatment is paramount. Current measures to curb the COVID-19 pandemic revolve
around a broad range of pharmaceutical remedies and the distribution of a vaccine
[4]. With vaccines being a prophylactic measure, current treatment options being
unproven, non-definitive and suboptimal, and the emergence of new viral strains,
attention needs to be placed on alternatives.
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Investigations have identified that the majority of Intensive Care Unit (ICU)
patients with COVID-19 have high plasma levels of granulocyte colony-stimulating
factor (GCSF), tumor necrosis factor-alpha (TNF-α), interferon gamma inducible
protein-10 (IP-10), monocyte chemoattractant protein-1 (MCP1) and macrophage
inflammatory protein 1-alpha (MIP1A) [5]. These factors have been shown to be
interconnected with the recruitment of proinflammatory cells and the production
of a cytokine storm. A cytokine storm is a large and abrupt increase in
proinflammatory cytokines that is suggested to be the main cause of acute respira-
tory distress syndrome (ARDS) and other severe pathophysiological effects seen in
COVID-19 patients [6]. The cytokine storm induces a vast signaling cascade that
recruits immune cells such as humoral B-cells, T-cells, and macrophages (MOs) as
well as shifts most of these cells into a proinflammatory state [7]. Interestingly,
clinicians have found that through the attenuation of the cytokine storm with
mesenchymal stem cells (MSCs) patients have been able to recover even in severe
cases [6].
MSCs have been successfully and safely used to treat pneumonia, acute lung
injury (ALI), and ARDS in the past [8, 9]. Their effectiveness has been attributed to
their ability to be directly antiviral, immunomodulate, induce tissue regeneration,
inhibit apoptosis/fibrosis and clear alveolar fluid [10]. MSCs have also been shown
to aggregate within the lung microvasculature when intravenously (IV) adminis-
tered, affecting the local environment in an efficient manner [11]. MSCs are able to
be so affective by inhibiting the function, recruitment and activation of MOs,
dendritic cells (DCs), T-cells and B-cells, subsequently reducing proinflammatory
cytokines such as interleukin-6 (IL-6) and TNF-α among others [12]. MSCs have
also been shown to differentiate into a multitude of tissues, and secrete cytokine
(CKs), growth factors (GFs) and extracellular vesicles (EVs), all of which play an
integral part in their mechanism of action [13, 14]. MSCs can be derived from
various types of tissues from both allogenic and autogenic sources. These tissues
include: adipose, bone marrow, placenta, amniotic fluid, umbilical cord, and
umbilical cord-derived Wharton jelly [15–18].
Extracellular vesicles (EVs) are composed of hypoimmunogenic properties that
resemble amphipathic structures such as the lipid bilayer that allow the vesicles to
migrate rapidly as well as harmlessly towards the target organs, without the occur-
rence of blood flow coagulations [19]. EVs can be obtained from any MSC source
and act in a paracrine manner delivering enclosed biological molecules such as
DNA, RNA, proteins, and lipids [20]. These EVs include microvesicles (MVs) and
exosomes and provide microenvironment that further decreases inflammation,
promotes tissue regeneration, and overall enhance the effects of MSCs [21].
In the face of the COVID-19 pandemic, scientists rush to generate and success-
fully distribute viable therapeutics and vaccines. Due to the urgent need and limi-
tations with the current options, MSCs and their EVs may be a viable option. The
cooperative mechanism of actions of MSCs and their EVs that include their ability
to be directly antiviral, immunomodulate, induce tissue regeneration, inhibit apo-
ptosis/fibrosis and clear alveolar fluid as well as sequester into the lung microvas-
culature make them an exciting alternative therapy.
2. Current treatments and therapeutic status
The scientific and medical community have been quick to adapt and have
explored a plethora of therapeutic approaches. Treatments originally known for
their efficacy against prior viral infections such as corticosteroids, and convalescent
plasma (CP) have been repurposed for SARS-CoV-2 [22–24]. Recent novel
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treatments and vaccines have emerged such as the monoclonal antibodies
casirivimab and imdevimab (REGN-COV2) and the Pfizer and Moderna mRNA
vaccines [4]. Unfortunately, these current treatments have limitations and poten-
tially dangerous adverse effects and although vaccinations are an effective preven-
tive measure, they do not treat COVID-19 [4]. Considering these limitations and
emergence of new viral strains there is an urgent need for a safe and effective
therapeutic option [25].
Corticosteroids have long been used due to their immunomodulation and they
have been a therapeutic option in many autoimmune diseases and in conditions
such as ARDS [26]. Although they have a long history, their use in COVID-19 still
remains controversial. Data from their prior use in viral infections indicated that
they were associated with increased mortality, longer hospitalizations and increased
tendency for mechanical ventilation [27–29]. In addition, observational studies in
patients with SARS and MERS suggested that the use of corticosteroids delayed viral
clearance, increased rates of secondary infections and had somewhat severe adverse
effects of psychosis, hyperglycemia, and avascular necrosis [27, 30, 31]. Thus,
similar adverse effects and outcomes can be expected in pateitns with COVID-19.
Passive immunity with convalescent plasma has also been used and has been shown
to improve the survival rate of patients with prior viral epidemics [32]. CP is a
therapy that utilizes artificial passive immunity from pooled plasma of patients with
resolved SARS-CoV-2 infections [32–33]. Although the science is sound, there are
several limitations associated with CP [34]. The efficacy of CP is highly reliant on
the time of its administration, as it seems to only be beneficial to patients a week
after infection when viremia is at its highest [35]. Additionally, the effect of CP on
SARS-CoV-2 is highly dependent on the neutralizing antibody titer which has to be
>1:160, seen 12 weeks after onset of disease [34].
CP infusions can also have severe adverse effects such as anaphylaxis, transfusion-
related ALI and cardiac overload. Additionally, there are several limitations to the
collection of CP such as age, weight, state of health, and informed consent all of
which make CP a limited treatment option to the current pandemic [34].
Recently attention have been geared towards novel treatments such as REGN-
COV-2, which is a cocktail of two human antibodies (casirivimab and imdevimab)
using both transgenic mice and B cells from recovered COVID-19 patients [36].
REGN-COV-2, although approved by the FDA, has specific criteria that have to be
met before a patient can receive it. REGN-COV-2 is authorized for use in mild to
moderate COVID-19 in adults, pediatric patients (12 years or older) with a weight
of 40 kg and who have had a positive SARS-CoV-2 test with a high risk of
progressing to severe COVID-19. Patients are not indicated for treatment if they are
hospitalized, require supplemental O2, and/or currently using chronic supplemental
O2 due to another underlying condition [37].These criteria are limitations and
important obstacles associated with REGN-COV-2.
Currently, the emergence of new vaccines against SARS-CoV-2 have drawn
much excitement. There are several vaccine candidates that are subdivided into five
general categories: protein subunit, virally vectored, nucleic acid (mRNA),
inactivated and live attenuated [23]. The Pfizer and Moderna vaccines utilize
nucleic acids (mRNA) and are composed of a lipid particle with nucleoside-
modified RNA, encoding for the S protein [38]. These two vaccines have the most
data and have been the most widely used [4]. Although the data suggest that these
vaccines are 95% effective at preventing SARS-CoV-2 infections they fail to actively
treat disease once patients develop symptoms leaving a substantial amount of the
population without a safe and efficacious treatment [38, 39].
Considering the limitations and adverse effects associated with current treatments
as well as vaccines being only a preventative measure the need to develop a safer and
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more efficacious therapy is vital. MSCs and their EVs lack severe adverse effects and
studies suggest they have high efficacy making them a potential candidate for
COVID-19 treatment. MSCs and their EVs immunomodulatory effects and regenera-
tive capabilities make them an exciting new option combating COVID-19 [12].
3. Mesenchmal stem cells (MSCs)
3.1 Origins of MSCs
In 1968, Friedenstein et al. isolated stem cells from the bonemarrow (BMSCs) of
mice [40]. The study showed that BM contained clonogenic progenitor cells and adher-
ent cells similar to fibroblasts, termed as a colony forming unit-fibroblast [40]. These
cells were found to have the ability to differentiate into chondrocytes, osteocytes,
osteoblasts and adipocytes in vitro [40]. In 1991, Arnold Caplan changed the terminol-
ogy to “Mesenchymal StemCell”, due to their similarities with stem cells frommeso-
dermal origins in embryonic tissues [41]. Later in 2017 Caplan suggested that the name
MSCbe alerted to “medicinal signaling cells” to accurately reflect their in vivo abilities of
acting as an in situmedication [42]. Currently, “Mesenchymal StemCell” is themost
common nomenclature, however Caplan didmanage to emphasize their function.
With the variations in nomenclature as well as controversy surrounding their
characteristics, the need for an official and concise criterion was needed. In 2006,
The International Society of Cellular Therapy (ISCT) established parameters with
four minimum criteria should be used to define MSCs. The criteria were quickly
accepted by the medical community and are the status quo currently [43, 44].
The ISCT criteria for MSCs: 1) Plastic adherence in standard culture condition,
2)Positive expression (≥95%) of CD105, CD90, CD73 cell surface antigens, 3) Low
expression (≤ 2%) of CD45, CD34, CD14, CD11b, CD79, CD19 and HLA-DR cell
surface antigens, 4)Potential to differentiate into osteoblasts, adipocytes and
chondrocytes in vitro.
3.2 MSC sources
MSCs can be differentiated by either being totipotent, pluripotent, multipotent,
or unipotent [45, 46]. Totipotent MSCs for example, can form both embryonic and
extraembryonic structures and proliferate indefinitely into cell types from all three
embryonic germ layers [45]. Multipotent MSCs or adult stem cell are the most
widely used and can differentiate into cell types from their respective source tissue
[46]. MSCs can then be further subdivided by their source tissue. Two of the most
common sources of MSCs are BM and adipose tissue. These are autologous sources
that have been studied substantially and have the most associated data. Both of
these sources require the patient to undergo an invasive procedure and are consid-
ered the first and second most reputable sources respectively for MSCs [47, 48].
Allogenic birth derived tissues such as umbilical cord (UC), UC-derived Wharton’s
jelly, amniotic fluid and placenta are also viable sources for MSCs. These sources
have advantages in relation to their availability, lack of invasiveness, and presence
of more pluripotent cells [12, 49, 50]. However, these sources have less data and do
not have such an extensive history of use in comparison with allogenic sources.
3.3 MSC’s mechanisms of action
MSCs have a long history of use in the treatment of viral lung infections,
pneumonia, ALI and ARDS [6, 12]. This prior literature has been used to support
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their current use in COVID-19. Studies have showed that when IV administered,
MSCs have specific and optimal mechanisms of action for the treatment of COVID-
19. MSCs are able to evade the body’s immune system and accumulate within the
lung microvasculature enabling them to act locally [51, 52]. They have direct anti-
viral activity, as well as anti-inflammatory, anti-apoptotic, and anti-fibrotic prop-
erties [47]. MSCs have also been touted for their ability to induce tissue regenera-
tion, transdifferentiate into cells and produce EVs [53].
IV infusion is the one of the most commonly used route for MSC delivery with
hundreds of clinical trials showing evidence of its safety [54]. A systematic review
and meta-analysis by Lalu et al. summarized the results of IV administered MSCs in
over 1000 patients [55]. The review indicated that there were no associated adverse
events within any of the studies and no patient developed any organ system com-
plications, infusion related toxicity, infections nor death [55]. In a study by Hwa Lee
et al. IV infused MSCs were shown to accumulate into emboli within the lungs with
no negative physiological effects [51]. In fact, the cells were noted to secrete TSG-6,
a potent anti-inflammatory, the effects of which were amplified due to the seques-
tration within the lung [51]. As immune privileged cells, MSCs can be used either
allogenically or autologously, due to their low levels of class I major histocompati-
bility complex (MHC) and class II MHC [52]. MSCs have also been shown to lack
the associated co-stimulatory molecules (B7–1, B7–2, CD40, CD80 and CD86)
needed to activate antigen presenting cells and the inflammatory process [52]. With
these factors in mind MSCs are primed to act locally within the lungs to effectively
and efficiently carry out their functions.
3.4 MSCs and immunomodulation
3.4.1 Innate immune response
In addition to the therapeutic potential of MSCs in regenerative medicine, for
which they been most known for, they have also shown promising results in the
regulation of immune responses [47]. MSCs through their ability to secrete
various soluble factors are able to suppress both the innate and adaptive immune
responses [47].
NOs and MOs both play a vital role in the innate immune response with DCs
being the gate keeper to the adaptive response [56]. MOs can be subdivided into M1
or M2 subtypes each with their own distinct functions [57]. The M1 subtype are well
known to be classically activated and responsible for phagocytosis, antigen presen-
tation to DCs and secretion of pro-inflammatory cytokines such as TNF-α, ΙL-1α,
IL-β, IL-6, IL-12 ultimately promoting a Th1 response [57]. The M2 subtype are
known for their high secretion of IL-10 promoting an anti-inflammatory Treg and
Th2 response along with inducing tissue remodeling and wound repair [57]. MSCs
have been shown to secrete prostaglandin E2 (PGE2) and induce a switch in the MO
population into an M2 subtype as well as substantially decreasing levels of IL-1β and
IL-6 [58]. Wahnon et al. further elucidated this anti- inflammatory switch by
reporting that the transcription factor signal transducer activators of transcription-3
(STAT3) activated in MSCs through cell to cell interactions between MOs produced
IL-10 and promoted an M2 phenotypic switch [59]. NO activation and function
have also been shown to be inhibited by MSCs. NOs are known to be a key compo-
nent of the innate immune response and in pathophysiology of ARDS. NOs when
activated release harmful reactive oxygen species, superoxide anions, peroxidases
and proteases that lead to diffuse alveolar damage, and accumulation of alveolar
fluid that underlie ARDS [60]. MSCs have been shown to secrete a potent antioxi-
dant enzyme, SOD3 that has been shown to decrease the release of peroxidases,
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proteases and the oxidative burst of NOs [61]. They have also able to directly engulf
dead NOs through ICAM-1 thereby further inhibiting release of their toxic contents
[61]. Secretion of tumor necrosis factor-inducible gene 6 protein (TSG-6) via MSCs
has also been shown to bind to IL-8 and CXCL8, inhibiting further migration,
extravasation and recruitment of NOs [62].
Immature DCs patrol peripheral tissues for foreign antigens and are activated by
cytokines (TNF-α, IL-1β, and IL-6) from M1 MOs [63]. Once immature DCs are
activated they mature into conventional DCs and present their cleaved epitopes on
their HLA complexes, inducing a pro-inflammatory Th1 and Th17 response [63].
PGE2 from MSCs has been shown to decrease CD38, CD80, CD86, IL-6, and IL-12
thereby decreasing DC function and pro-inflammatory T cell responses [64].
Preventing the maturation of these conventional DCs is vital in order to prevent this
T cell response and the associated pro inflammatory state. Furthermore, DC matu-
ration was inhibited by the inactivation of MAPK and NF-κB signaling cascades via
the secretion of the TSG-6 [65]. In a study by Chen et al. DC maturation was
induced from a conventional (pro-inflammatory) DC into a plasmacytoid DC pop-
ulation by PGE2 from MSCs, shifting the T cell population into a Th2 (anti-
inflammatory) subset [66]. In addition, specific miRNAs (miR-21-5p, miR-142-3p,
miR-223-3p, miR-126-3p) within EVs of MSCs have shown to further attenuate the
DC maturation process [67].
3.4.2 Adaptive immune response
MSCs role in modulating T and B cell responses begins with their attenuation of
MO and DC functions and continues with PGE2 from MSCs. PGE2 has been proven
to increase the production of cAMP in T cells down regulating IL-2, and the IL-2
receptor as well as inhibiting the release of intracellular Ca2+ resulting in the direct
inhibition of T cell activation [68]. PGE2 has also been shown to inactivate T cells
via the hydrolysis of phosphatidylinositol, diacylglycerol and inositol phosphate
[68]. In addition, PGE2 promotes a Th2 and a T reg shift in the T cell population
overall influencing immunosuppression and an anti-inflammatory response
[13, 69]. MSCs through their secretion of IDO, PGE2, TGF-β1, and Hepatocyte
growth factor (HGF) have also been shown to induce G0/G1 cell cycle arrest in T
cells and B cells [70, 71]. Nitric oxide (NO) from MSCs has shown to play a role in
this by suppressing the phosphorylation of signal transducer and activator of tran-
scription 5, thereby inhibiting TCR activated T cell proliferation and production of
cytokines [72]. Studies have also suggested that MSCs can induce T cell and B cell
apoptosis through direct cell to cell contact. Utilizing their interactions with the Fas/
Fas ligand, TNF-related apoptosis-inducing ligand/death receptor signaling and
programed death ligand-1/programmed death-1 pathways have shown to promote
T and B cell apoptosis [73, 74]. This process was especially seen in CD4+, CD8+ and
Th17 cells with a synergistic increase in T reg cells [75]. The down regulation of
CXCR4, and CXCR5 via MSCs has shown further evidence of inhibiting B cell
migratory abilities towards chemoattractant agents such as CXCL12 and CXClL13
[74]. Lastly, GM-CSF from MSCs have been recognized as having inhibitory actions
on the production of CXCR4, CXR5, IL-6, and IL-7 while having no negative effects
on IL-4 and IL-10 from B cells with a net anti-inflammatory affect [74].
3.5 MSC’s additional mechanisms of action
Studies have shown that MSCs have been effective in inhibiting the viral repli-
cation of influenza, hepatitis B, herpes simplex, cytomegalovirus and the measles
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virus [76–79]. In a study by Khatri et al. MSCs had the ability to inhibit viral
replication, shedding and lung damage in a porcine model with influenza induced
pneumonia [76]. MSC-derived EVs were shown to be the key players in this process
via their transfer of RNAs to virus infected epithelial cells. Lung epithelial cell
apoptosis, hemagglutination and viral shedding were all significantly reduced in the
study [76]. MSC-derived EVs have also demonstrated to decrease pro-inflammatory
cytokine while increasing IL-10 and increase T regs [76]. IDO via MSCs has also
been shown to directly decrease viral replication in most of the viruses that have
been studied [76–79].
The secretion of various CKs, GFs and EVs have been reported to promote tissue
regeneration and inhibit apoptosis, tissue fibrosis and alveolar fluid accumulation.
As previously elucidated, M2 MOs promote anti-inflammatory Treg and Th2
responses while inducing tissue remodeling and wound repair [57]. Direct tissue
regeneration from MSCs has been attributed to keratinocyte growth factor (KGF),
vascular endothelial growth factor (VEGF), and hepatocyte growth factor (HGF) all
of which have also been known to contribute to the in decrease collagen build up
and fibrosis [80, 81]. In an in vivo bleomycin-induced pulmonary fibrosis model,
Aguilar et al. noted that KGF was the key factor in the inhibition of collagen
accumulation, promoting endogenous type II pneumocyte proliferation and overall
attenuation of lung damage [82]. Previous studies have also further characterized
KGF as being a potent factor in lung epithelial cell proliferation, while simulta-
neously being capable to increase matrix metalloproteinase-9 (MMP-9), IL-1RA and
promoting clearance of apoptotic cells and inhibiting fibrosis [82, 83]. Gazdhar et al.
used an in vivo bleomycin induced lung injury model in which he found that MSC-
derived HGF was able to inhibit lung fibrosis and induce alveolar epithelial repair
by decreasing TGF-B and α-smooth muscle actin expression [84]. The positive
effects of HGF was further studied by Wang et al. who showed that MSC-derived
HGF was responsible for increasing endothelial cell proliferation, intercellular
junction proteins (VE-cadherin and occludin), and IL-10 while decreasing IL-6 and
overall apoptosis [85]. MSC-derived VEGF and HGF have also shown to be able to
stabilize Bcl-2 and inhibit pro-apoptotic factors hypoxia-inducible factor-1α pro-
tein, Bnip3 and CHOP contributing to their anti-apoptotic and anti-fibrotic effects
[86]. In addition to the intracellular stabilization via these aforementioned GFs,
factors such as MSC derived aniopoietin-1, and EVs have shown to induce alveolar
fluid clearance within the lungs adding in their therapeutic benefits in ARDS [87].
In a study by Zhu et al. using an E.coli endotoxin-induce ALI model, MSC-derived
EVs showcased their ability to transfer mRNA encoding for KGF inhibiting NOs,
pulmonary edema and lung permeability [88].
4. Extracellular vesicles
Extracellular vesicles (EVs) are currently being studied as potential
therapeutic agents for immune related pathologies due to their
immunomodulatory and regenerative properties [89]. Interest in EVs has grown
due to their ability to have similar therapeutic effects as MSCs as a cell free therapy
[89]. What was once viewed as cellular waste products, may now have the potential
to treat one of the largest natural disasters in modern history that is the COVID-19
pandemic.
The field of EVs has grown significantly in the recent years leading to the
formation of the International Society for Extracellular Vesicles (ISEV) [89]. ISEV
defines EVs as particles naturally released from a cell that are delimited by a lipid
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bilayer and cannot replicate [90]. EVs are further subclassified as exosomes
(40-120 nm), microvesicles (50-1000 nm), and apoptotic bodies (500-2000 nm).
Both microvesicles and apoptotic bodies bud-off directly from the cellular mem-
brane and participate in two distinct cellular pathways: apoptotic bodies are prod-
ucts of cell mediated death whereas microvesicles are involved in paracrine
communication [89, 91]. Exosome biogenesis, however, differs greatly in that it
involves cell membrane invagination and formation of an intraluminal vesicles that
undergoes modification in what is called a multivesicular body (MVB) [92]. Once
modifications are performed, the MVB fuses with the cell membrane and the ILV’s
are secreted into the extracellular space as exosomes [92].
Once secreted, EV’s carry a variety of nucleic acids, proteins, and lipids that
can regulate or alter a plethora of biological processes through effects on cell recep-
tors, adhesion molecules, cytokines, and other cell signaling molecules [89, 93–96].
They have attracted significant attention for their ability to inhibit tumorigeneses,
suppress immune responses, promote tissues repair, and have therapeutic effects on
neurological disease [96]. A recent study by Schultz et al. performed bioinformatic
analysis of mRNA and miRNA cargo of EV’s using Gene Expression Omnibus
(GEO) database and miRWalk 3.0 servers. The study found that 266 miRNA’s
within exosomes have the ability to attenuate cell death by inhibiting TNF-a, IFN-y,
JAK2, and JAK1 among others. Similarly, 148 miRNA’s were identified with 1 or 2
targets of molecules involved in the intrinsic and extrinsic coagulations cascade
pathways [97]. Continually, EV’s also have the capability of replenishing glycolytic
enzymes such as glyceraldehyde 3-phosphate dehydrogenase (GAPDH), phospho-
glycerate kinase (PGK), phosphoglucomutase (PGM), enolase (ENO), and pyru-
vate kinase m2 isoform (PKm2), and phosphorylated PFKFB3, all of which are
involved in the production of glycolytic ATP. It was proposed that secretions of
these enzymes can reduce levels of reactive oxygen species and consequently
halt cellular death [96]. In addition, matrix metalloproteinase (MMP)-9,
vascular endothelial growth factor (VEGF), extracellular and matrix
metalloproteinase inducer (EMMPRIN) have also been found within exosomes
further postulating their regenerative effects through angiogenesis stimulation and
tissue repair [96].
In preclinical trials, EV’s have already demonstrated their immunomodulatory
capabilities. In a study by Monsel et al. [98] on pneumonia induced mice, EV’s
reduced neutrophils and macrophages by 73% and 49% respectively, while
decreasing edema and permeability of the endothelial-epithelial barrier to protein
[99]. In fact, a recent study demonstrated that EV’s reduce levels of inflammatory
interleukins: IL-8, IL-6, IL-17 and TNF-α, when transferring anti-apoptotic miR-
21-5p to target cells which resulted in reduced edema and lung dysfunction [100].
Additionally, EV’s have also demonstrated their efficacy against acute lung injury
(ALI) through downregulation of TLR/NF-κB signaling in rat models [101]]. A
recent study assessed the safety and efficacy of EVs on patients with severe
COVID-19 infections. 24 patients were recruited under the specified trial criteria
and followed for 14 days [102]. In addition to not having any notable adverse
effects to the 15 mL IV dose of exosomes, the experimental group exhibited
lower neutrophil count, c-reactive protein, ferritin, and D-dimer indicating
an immunomodulatory effect [102]. Additionally, the overall survival rates
were 83% with 17/24 patients fully recovered and 3/24 in stable conditions
[102]. The study actively demonstrated EVs ability to safely attenuate the
cytokine storm associated with severe COVID-19 infections. To fully appreciate
the impact of EVs on COVID-19, further studies should be developed. As of
February 18, 2021, applying the search word “exosomes” or “extracellular vesicles”
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and “COVID-19” on clinicaltrials.gov, results in 9 and 5 listed clinical trials, respec-
tively. One of these trials, (NCT04491240) evaluated the safety and efficacy of
exosome inhalation in SARS-CoV-1 pneumonia. Although results are published in c
linicaltrails.gov, publication of the article is pending. The same experiment, how-
ever, has been approved for phase 2 and is currently enrolling participants
(NCT04602442).
The field of EV’s continues to show increasing promise as a therapeutic in the
battle against COVID-19 based on their ability to carry a variety of cellular and
nuclear components in a stable and hypoimmunogenic bilayer [6, 19].
5. MSCs and COVID-19
Due to the mechanisms of action of MSCs as well as their success as a therapy in
ALI and ARDS, MSCs have attracted the attention now for their possible use in
COVID-19. Leng et al. conducted one of the first studies exploring the case for
MSCs in COVID-19 [103]. Ten adult patients with a positive real-time reverse
transcription polymerase chain reaction assay and that meet the clinical classifica-
tion for COVID-19 by the National Health Commission of China were enrolled in
the study. Of the ten patients seven patients were in the treatment group, of those
seven one was categorized as critically severe type, four were severe, and two were
common types. MSCs were administered via IV infusion with 1 x 106 cells per
kilogram and patients were assessed for a 14 day period. Two-four days after
infusion all patients with symptoms of a high fever, weakness, shortness of breath
and low oxygen saturation resolved. None of the patients experienced any infusion-
related nor allergic reactions with no delayed hypersensitivity reactions or infec-
tions. Three of the patients that subsequently recovered were discharged 10 days
after treatment with one of them being characterized as a severe subtype. In regard
to the patient having a critically severe type of COVID-19, their C-reactive protein
(CRP) decreased from 19.0 g/L to 10.1 g/L, and their oxygen saturation (SaO2)
increased from 89–98% without supplemental O2. The critically severe patient also
had significant improvements in lymphopenia, as well as in indicators of liver,
myocardial and kidney damage/disease (aspartic aminotransferase, creatine kinase
and myoglobin). Chest CT imaging with the characteristic ground-glass opacity
and pneumonia infiltration were also reduced by the 9th day after MSC infusion.
Overall levels of pro-inflammatory CD4+/CD8+ T cells, TNF-α and conventional
DCs all decreased while IL-10, VEGF, HGF and TGFβ increased, promoting a tissue
regeneration state. It was also concluded that MSCs were ACE2R and TMPRSS2
negative, theoretically making them immune from possible SARS-COV-2 infection
[103]. Additionally, evidence by Sanches-Guijo et al. indicated similar results [104].
Adipose-derived MSCs were used as a treatment for 13 COVID-19 patients. There
were no adverse events in the MSC treatment group with no worsening of respira-
tory or hemodynamic parameters. Clinical improvement was seen in 70% of the
patients, seven of them extubated and discharged, and two showing signs of
improvement in their ventilatory and radiological parameters, two resulting in
fatalities and the rest of the patients in stable condition. Overall levels of CRP,
IL-6, ferritin, and D-dimer were decreased [104].These positive effects of
MSCs in COVID-19 were further elucidated by Tang et al., the study included
two patients with COVID-19 which received three separate IV infusions of
menstrual blood derived MSCs [105]. The first patient (Patient 1) was a 37 year
old woman with a past medical history of hypertension. Patient 1’s levels of
CRP, TNF-α, and IL-6 decreased while their SaO2 dramatically increased from 98%
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on 100% fraction of inspired O2 (FiO2) to 97% SaO2 on 55% FiO2. Initial CXR
findings revealed large, patches of high density lesions in bilateral lungs that
resolved with treatment along with viral RNA testing. Patient 2 was a 71 year
old male that similar improvements in inflammatory markers, SaO2 and CXR
findings [105].
Recently, a study conducted by Shi et al. used UC-derived MSCs as a therapeutic
in 101 patients diagnosed with severe COVID-19 [106]. The study was a double-
blind, placebo-controlled phase 2 trial with 101 patients randomized in a 2:1 ratio
with sixty six patients, with one patient withdrawing, in the treatment group and 35
in the placebo group. Overall chest CTs, age, sex, BMI, and onset of symptoms
matched between the groups. The occurrence of adverse events during the study
was similar between the treatment (55.38%) and the placebo group (60%) with
none directly related to the MSCs. Three IV infusions of UC-derived MSCs with 4 x
107 cells per infusion were administered. High resolution chest CT images were
assessed using both radiologist and artificial intelligence software to estimate the
total lesion proportion (TLP) via the Hodges-Lehmann estimator of the entire lung.
The median change in the TLP was 19.40% in the treatment group 7.30% in the
placebo group with the overall difference of 13.31%. Solid lesions were found to
decrease by 57.70% in the treatment group with an overall decrease in the ground-
glass lesions. A 6-minute walk test (6-MWT) was used to assess the restoration of
lung function and reserve capability in both groups. The median 6-MWT was 420
meters in the MSC treatment group in comparison with 403 meters in the placebo
group [106]. In a similar study using UC-MSCs for COVID-19, Lanzoni et al.
conducted a double-blind, phase 1/2a, randomized controlled trial [107]. Twenty-
four patients hospitalized for COVID-19 were randomized 1:1 into either the treat-
ment or control group. Two infusions of UC-derived MSCs with 100  20 x 106
MSCs in each were administered. There were two serious adverse events (SAEs)
observed in the treatment group while the control group had 16 SAEs, the inter-
vention was deemed safe as it did not lead to an increase in specified infusion
related AEs. Overall, the survival rate in the treatment group was far greater than in
the control group with 91% of subjects in the treatment group surviving 31 days
post first infusion in comparison with 42% in the control group. The time of
recovery was also shorter for the MSC group, with a hazard ratio for recovery in the
control group vs. the MSC group of 0.29 indicating a lower rate of recovery in the
control group. Concentrations of GM-CSF, IFN- y, IL-5, IL-6, IL-7, TNF-α, TNF-β,
were also statistically decreased in the MSC treatment group in comparison with
control [107].
With the current supporting data surrounding the use of MSCs in COVID-19 as
well as their historical efficacy in lung injury models the case for their use on a
compassionate basis can be made. In the future more randomized, controlled,
multi-centered clinical trials are needed in order to increase the knowledge of the
use of MSCs in COVID-19.
6. Ongoing clinical trials
Clinical trials that utilize MSCs and EVs and that are registered on
ClinicalTrials.gov can be seen in Table 1. and Table 2 respectively. The data
from current studies are promising and promotes the use of MSCs and EVs as a
possible treatment for COVID-19. However, more multi-center, controlled, ran-
domized clinical trias are needed to further solidify the use of MSCs and EVs in
COVID-19.
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Study
Identifier
Stem Cell Source Study Phase;
Estimated
Enrollment (N)
Primary Outcome Measure(s) Recruitment
Status
Country
NCT04313322 Wharton’s Jelly Mesenchymal stem cells Phase I;
N = 5
Clinical outcome (Time Frame: 3 weeks); CT Scan (Time
Frame: 3 weeks); RT-PCR results (Time Frame: 3 weeks)
Recruiting Jordan




Adverse reactions incidence (Time Frame: Day 0–28); Rate
of mortality within 28-days (Time Frame: Day 0–28); Time
to clinical improvement on a seven-category ordinal scale




NCT04428801 Autologous adipose-derived stem cells Phase II;
N = 200
Tolerability and acute safety of AdMSC infusion by
assessment of the total number of AEs/SAEs related and
non-related with the medication (Time Frame: 6 months);
The overall proportion of subjects who develop any AEs/
SAEs related and non-related with the AdMSC infusions as
compared to the control group (Time Frame: 6 months);
COVID-19 incidence rates in both the study and control




NCT04444271 Bone marrow derived Mesenchymal stem cells Overall survival (Time Frame: 30 days post intervention) Recruiting Pakistan
NCT04416139 Umbilical Cord Mesenchymal stem cells Phase II;
N = 10
Functional Respiratory changes: PaO2/FiO2 ratio (Time
Frame: 3 weeks); Clinical cardiac changes: Heart rate per
minute (Time Frame: 3 weeks); Clinical Respiratory
Changes: Respiratory rate per minute (Time Frame:
3 weeks); Changes in body temperature (Time Frame:
3 weeks)
Recruiting Mexico
NCT04486001 Adipose-derived allogeneic Mesenchymal stem cells Phase I;
N = 20
Frequency of all adverse events (Time Frame: Through
study completion, an average of three months); Frequency
of infusion related serious adverse events (Time Frame:
6 hours post infusion); Frequency of serious adverse events
(Time Frame: Through study completion, an average of
three months)
Recruiting USA

























































Stem Cell Source Study Phase;
Estimated
Enrollment (N)
Primary Outcome Measure(s) Recruitment
Status
Country
NCT04565665 Cord Blood-Derived Mesenchymal stem cells Phase I;
N = 70
Incidence of composite serious adverse events (Pilot) (Time
Frame: Within 30 days of the first mesenchymal stem cell
(MSC) infusion); Patients alive without grade 3, 4
infusional toxicity (Phase II) (Time Frame: At day 30 post
MSC infusion); Patients alive with grade 3 or 4 infusional
toxicity (Phase II) (Time Frame: At day 30 post MSC
infusion); Patients not alive (Phase II) (Time Frame: At day
30 post MSC infusion)
Recruiting USA
NCT04429763 Umbilical cord derived Mesenchymal stem cells Phase II;
N = 30
Clinical deterioration or death (Time Frame: 4 weeks) Not yet
recruiting
Colombia
NCT04315987 Mesenchymal stem cells (source not defined) Phase II;
N = 90
Change in Clinical Condition (Time Frame: 10 days) Not yet
recruiting
Brazil













Safety of the administration of allogeneic mesenchymal
stem cells derived from adipose tissue assessed by Adverse
Event Rate (Time Frame: 12 months); Efficacy of the
administration of allogeneic mesenchymal stem cells





NCT04348435 Allogeneic Adipose-derived Mesenchymal stem cells Phase II;
N = 100
Incidence of hospitalization for COVID-19 (Time Frame:
week 0 through week 26); Incidence of symptoms





NCT04611256 Adipose tissue derived-Mesenchymal stem cells Phase I;
N = 20
Change form baseline in Arterial oxygen saturation (Time
Frame: up to 25 days); Change form baseline in Arterial
oxygen saturation (Time Frame: up to 25 days); Days to



















Stem Cell Source Study Phase;
Estimated
Enrollment (N)
Primary Outcome Measure(s) Recruitment
Status
Country
NCT04625738 Wharton’s Jelly Mesenchymal stem cells Phase II;
N = 30
PaO2/FiO2 ratio (Time Frame: day 10) Not yet
recruiting
France
NCT04252118 Umbilical cord derived Mesenchymal stem cells Phase I;
N = 20
Size of lesion area by chest radiograph or CT (Time Frame:
At Baseline, Day 3, Day 6, Day 10, Day 14, Day 21, Day 28);
Side effects in the MSCs treatment group (Time Frame: At
Baseline, Day 3, Day 6, Day 10, Day 14, Day 21, Day 28,
Day 90 and Day 180)
Recruiting China
NCT04273646 Human Umbilical Cord Mesenchymal stem cells Not Applicable;
N = 48
Pneumonia severity index (Time Frame: From Baseline
(0 W) to 12 week after treatment); Oxygenation index
(PaO2/FiO2) (Time Frame: From Baseline (0 W) to




NCT04349631 Autologous Adipose-derived Mesenchymal stem cells Phase II;
N = 56
Incidence of hospitalization for COVID-19 (Time Frame:
Week 0 through week 26); Incidence of symptoms for




NCT04346368 Bone Marrow-derived Mesenchymal stem cells Phase I/II;
N = 20
Changes of oxygenation index (PaO2/FiO2) (Time Frame:
At baseline, 6 hour, Day 1, Day 3, Week 1, Week 2, Week 4,
Month 6); Side effects in the BM-MSCs treatment group








Number of cured patients (Time Frame: 3 weeks) Enrolling by
invitation
Belarus
NCT04288102 Umbilical cord derived Mesenchymal stem cells Phase II;
N = 100
Change in lesion proportion (%) of full lung volume from
baseline to day 28. (Time Frame: Day 28)
Completed China
NCT04629105 Mesenchymal stem cells (source not defined) Phase I;
N = 70
Incidence of Treatment-Emergent Serious Adverse Events
(Time Frame: Within 4 weeks after treatment); Number of
Participants with Abnormal Clinical Significant Laboratory
Values in Hematology (Time Frame: Baseline to 6 Months);
Number of Participants with Changes in Echocardiography






















































Stem Cell Source Study Phase;
Estimated
Enrollment (N)
Primary Outcome Measure(s) Recruitment
Status
Country
Number of Participants with Changes to overall assessment
of Electrocardiogram (Time Frame: Baseline to 6 Months);
Time to recovery of Sp02 (Time Frame: Baseline to
6 Months); Number of Participants with Abnormal Clinical
Significant Lab Values in the Blood Chemistry testing
(Time Frame: Baseline to 6 months); Number of
Participants with Abnormal Clinical Significant Lab Values
in the Coagulation (Time Frame: Baseline to 6 months);
Number of Participants with Abnormal Clinical Significant
Lab Values in the Urinalysis (Time Frame: Baseline to
6 months)




Treatment related adverse events (Time Frame: From
baseline to Week 12); Number of subjects with treatment
related abnormal variation of vital signs, physical
examination and laboratory test values (Time Frame: From





NCT04366063 Mesenchymal stem cells (source not defined) Phase II/III;
N = 60
Adverse events assessment (Time Frame: From baseline to
day 28); Blood oxygen saturation (Time Frame: From
baseline to day 14)
Recruiting Iran




Survival Rates (Time Frame: 30 Days); Contraction Rates
(Time Frame: 30 Days)
Completed USA
NCT04302519 Dental pulp mesenchymal stem cells Early Phase I;
N = 24





NCT04437823 Umbilical cord derived Mesenchymal stem cells Phase II;
N = 20
Safety and efficacy assessment of infusion associated
adverse events (Time Frame: Day 01 to Day 30); Chest
Radiograph or Chest CT Scan (Time Frame: Day 01 to Day
30)
Recruiting Pakistan
NCT04494386 Umbilical Cord Lining Stem Cells Phase I/II;
N = 60
Incidence of Dose Limiting Toxicity (DLT) (Time Frame:



















Stem Cell Source Study Phase;
Estimated
Enrollment (N)
Primary Outcome Measure(s) Recruitment
Status
Country
suspected adverse reaction (SAR), or serious adverse event
(SAE) (Time Frame: 1 week); Treatment-emergent adverse
events (AE) and serious adverse events (SAE) (Time
Frame: 1 month); Treatment-emergent adverse events (AE)
and serious adverse events (SAE) (Time Frame: 12 months)
NCT04457609 Umbilical Cord Mesenchymal stem cells Phase I;
N = 40
Clinical improvement: Presence of dyspnea (Time Frame:
15 days); Clinical improvement: presence of sputum (Time
Frame: 15 days); Clinical improvement: fever (Time Frame:
15 days); Clinical improvement: ventilation status (Time
Frame: 15 days); Clinical improvement: blood pressure
(Time Frame: 15 days); Clinical improvement: heart rate
(Time Frame: 15 days); Clinical improvement: respiratory
rate (Time Frame: 15 days); Clinical improvement: oxygen
saturation (Time Frame: 15 days)
Recruiting Indonesia




The immune function (TNF-α IL-1β IL-6 TGF-β IL-8 PCT
CRP) (Time Frame: Observe the immune function of the
participants within 4 weeks); Blood oxygen saturation
(Time Frame: Monitor blood oxygen saturation of the
participants within 4 weeks)
Recruiting China
NCT04392778 Umbilical Cord-derived Mesenchymal stem cells Phase I/II;
N = 30
Clinical improvement (Time Frame: 3 months) Recruiting Turkey




Percent of participants with treatment related Serious








Incidence of pre-specified infusion associated adverse
events (Time Frame: Day 5); Incidence of Severe Adverse
Events (Time Frame: 90 days)
Completed USA
NCT04522986 Adipose-derived Mesenchymal stem cells Phase I;
N = 6























































Stem Cell Source Study Phase;
Estimated
Enrollment (N)
Primary Outcome Measure(s) Recruitment
Status
Country
NCT04371601 Umbilical Cord-derived Mensechynmal stem cells Early Phase I;
N = 60
Changes of oxygenation index (PaO2/FiO2), blood gas test




NCT04362189 Allogeneic Adipose-derived Mesenchymal stem cells Phase II;
N = 100
Interleukin-6 (Time Frame: screening, day 0, 7, 10); C
Reactive protein (Time Frame: screening, day 0, 7, 10);
Oxygenation (Time Frame: screening, day 0, 7, 10); TNF
alpha (Time Frame: screening, day 0, 7, 10); IL-10 (Time
Frame: screening, day 0, 7. 10); Return to room air (RTRA)




NCT04390152 Wharton’s Jelly derived Mesenchymal stem cells Phase I/II;
N = 40





NCT04461925 Placenta-Derived MMSCs; Cryopreserved Placenta-
Derived Multipotent Mesenchymal Stromal Cells
Phase I/II;
N = 30
Changes of oxygenation index PaO2/FiO2, most
conveniently the P/F ratio. (Time Frame: up to 28 days);
Changes in length of hospital stay (Time Frame: up to
28 days); Changes in mortality rate (Time Frame: up to
28 days)
Recruiting Ukraine
NCT04299152 Human cord blood stem cells Phase II;
N = 20
Determine the number of Covid-19 patients who were








Efficacy of the administration of allogeneic mesenchymal
stem cells derived from adipose tissue assessed by Survival
Rate) (Time Frame: 28 days); Safety of the administration
of allogeneic mesenchymal stem cells derived from adipose














NCT04393415 Cord blood stem cells Not Applicable;
N = 100
The number of patients with positive covid 19 who will



















Stem Cell Source Study Phase;
Estimated
Enrollment (N)
Primary Outcome Measure(s) Recruitment
Status
Country




The incidence of pre-specified treatment related adverse
events of interest (TRAEIs). (Time Frame: From drug
administration to day 10 post-infusion)
Recruiting Sweden




Incidence of AEs (Time Frame: 30 days); Mortality (Time
Frame: 30 days); Death (Time Frame: 30 days); Number of
ventilator-free days (Time Frame: 60 days)
Recruiting USA
NCT04452097 Human umbilical cord Mesenchymal stem cells Phase I/II;
N = 39
Incidence of infusion-related adverse events (Time Frame:
Day 3); Incidence of any treatment-emergent adverse
events (TEAEs) and treatment emergent serious adverse




NCT04377334 Allogeneic bone marrow-derived human
mesenchymal stem (stromal) cells
Phase II;
N = 40
Lung injury score (Time Frame: day 10) Not yet
recruiting
Germany




Adverse reaction (AE) and severe adverse reaction (SAE)
(Time Frame: Within 28 days after treatment); Changes of
lung imaging examinations (Time Frame: Within 28 days
after treatment)
Recruiting China
NCT04345601 Bone Marrow Mesenchymal Stromal Cells Early Phase I;
N = 30
Treatment-related serious adverse events (tSAEs) (Time
Frame: 28 days post cell infusion); Change in clinical status




NCT04390139 Wharton-Jelly mesenchymal stromal cells Phase I/II;
N = 30
All-cause mortality at day 28 (Time Frame: Day 28) Recruiting Spain




Mortality at day 30 (Time Frame: 30 days post treatment) Not yet
recruiting
USA
NCT04400032 Bone Marrow derived Mesenchymal Stromal Cells Phase I;
N = 9
Number of Participants With Treatment-Related Adverse
Events as Assessed by CTCAE v4.0 (Time Frame: At time of






















































Stem Cell Source Study Phase;
Estimated
Enrollment (N)
Primary Outcome Measure(s) Recruitment
Status
Country




Trend in trajectory of PaO2/FiO2 ratio (P/F ratio) between
groups (Time Frame: 7 days)
Recruiting Australia
NCT04467047 Allogenic Bone Marrow Mesenchymal Stromal Cells Phase I;
N = 10
Overall survival (Time Frame: 60 days) Not yet
recruiting
Brazil
NCT04365101 Natural Killer (NK) cells derived from human
placental hematopoietic stem (CD34+) cells
Phase I/II;
N = 86
Phase 1: Frequency and Severity of Adverse Events (AE)
(Time Frame: Up to 12 months); Phase 1: Rate of clearance
of SARS-CoV-2 (Time Frame: Up to 12 months); Phase 1:
Rate of clinical improvement (Time Frame: Up to
12 months); Phase 2: Time to Clearance of SARS-CoV-2
(Time Frame: Up to 28 days); Phase 2: Time to Clinical
Improvement by NEWS2 Score (Time Frame: Up to
28 days)
Recruiting USA




Oxygenation index (OI) (Time Frame: Day 7); Incidence of
Serious Adverse Events (SAEs) (Time Frame: 28 days)
Recruiting United
Kingdom
NCT04269525 Umbilical cord derived Mesenchymal stem cells Phase II;
N = 16
Oxygenation index (Time Frame: on the day 14 after
enrollment)
Recruiting China




Proportion of patients who have achieved withdrawal of
invasive mechanical ventilation (Time Frame: 0–7 days);
Rate of mortality (Time Frame: 28 days)
Recruiting Spain




Respiratory efficacy evaluated by the increase in PaO2/FiO2
ratio from baseline to day 7 in the experimental group
compared with the placebo group (Time Frame: From








Number of all-cause mortality (Time Frame: 30 days) Active, not
recruiting
USA




Ventilator-Free Days (Time Frame: Day 0 through Day 28);



















Stem Cell Source Study Phase;
Estimated
Enrollment (N)
Primary Outcome Measure(s) Recruitment
Status
Country
treatment-emergent adverse events as assessed by CTCAE
v5.0. (Time Frame: Day 28)




To assess the safety of Descartes-30 in patients with
moderate-to-severe ARDS (Time Frame: 2 years)
Recruiting USA




Safety and tolerability as measured by incidence of IP-
related serious adverse events (Time Frame: Outcomes and
Serious Adverse Events through Day 180)
Recruiting USA




Incidence of grade 3–5 infusional toxicities and predefined
hemodynamic or respiratory adverse events related to the
infusion of mesenchymal stem cells (Time Frame: Within
6 hours of the start of the infusion)
Recruiting USA
Table 1.








































































during trial (Time Frame:
through study, an average
of 2 months); Number of
participants with non-
serious and serious adverse
during inhalation procedure













during trial (Time Frame:
30 days after clinic
discharge); Number of
participants with non-
serious and serious adverse
during inhalation procedure
(Time Frame: after each
inhalation during 10 days)
Completed Russia




Adverse reaction (AE) and
severe AE (SAE) (Time
Frame: 28 days); Efficacy
Assessment – Time to
Clinical Recovery (Time
Frame: 28 days); The rate of
recovery without
Mechanical Ventilator









Incidence of any infusion
associated adverse events
(Time Frame: 60 days);




NCT04493242 Bone Marrow Phase II;
N = 60
All-cause mortality (Time
Frame: 28 days); Median











Adverse reaction and severe
adverse reaction (Time
frame: up to 28 days); time
to clinical improvement












Clinical trials registered on ClinicalTrials.gov till January 5, 2021 utilizing extracellular vesicles and/or
exosomes for the treatment of COVID-19.
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7. Conclusion
The current pandemic we are encountering has placed an unprecedented burden
upon the world and is likely to leave an everlasting impact for generations to come.
With the lack of definitive and safe treatment along with the congruent rise in
unknown viral variants the demand for a safe source of mitigation is urgently
needed. Clincial studies have specified tht patients who suffer from SARS-CoV-2
related ARDS have an indued cytokine storm composed of a large and rapid surge in
pro-inflammatory cytokines and inflammatory cells. MSCs and their EVs have a
long been touted for their safty and effectiveness in the treatment of immune
related diseases, ALI and ARDS. MSCs and EVs have are now being repourposed for
COVID-19 due to their antiviral, anti-inflammatory and tissue regenerative capa-
bilities. Data from clinical trials using MSCs and EVs have shown promising results
that warrant their use on a compassionate basis for COVID-19. Eventually more
pre-clinical and clinical trials are needed to further establish the safety and efficacy
of MSCs and their EVs as a potential treatment for COVID-19.
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